Evaluating Diabetes Patients’ Preferences for Profiles of Glp-1 Treatments In The United Kingdom: A Discrete Choice Experiment

Gelhorn, HL; Poon, JL; Davies, EW; Paczkowski, Rosirene; Curtis, SE; Boye, KS

doi:10.1016/j.jval.2015.09.2133

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weekly injections have the potential to improve patient perceptions. In fact, a study of injection-naive patients with T2D demonstrated that 83% of patients' significantly preferred a once weekly dulaglutide medication profile compared to a once daily liraglutide medication profile (p ≤ 0.0001) [35].…”

Section: Device and Delivery Benefitsmentioning

confidence: 99%

“…Two such studies involved obtaining stated preferences from patients with T2D. In the first study, using discrete choice experiment (DCE) methodology, in-person interviews were conducted in the UK with injection-naive patients with T2D [35]. The DCE examined six attributes of T2D treatment associated with dulaglutide and liraglutide: 'dosing frequency,' 'HbA1c change,' 'weight change,' 'type of delivery system,' 'frequency of nausea,' and 'frequency of hypoglycemia.'…”

Section: Pros In Dulaglutide Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers

Anderson¹,

Thieu

Boye

et al. 2016

Postgraduate Medicine

View full text Add to dashboard Cite

Approximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes (PRO), and clinical data surrounding the dulaglutide administration device. Dulaglutide 1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatide BID, and insulin glargine (in 2 trials), and non-inferiority to liraglutide in reduction of HbA1c from baseline, with an acceptable safety profile. Dulaglutide-treated patients achieved the composite endpoint of an HbA1c <7.0% with no hypoglycemia, no severe hypoglycemia, and no weight gain significantly more than metformin, sitagliptin, exenatide BID or insulin glargine treated patients. Dulaglutide consistently showed an early onset of glycemic control, lasting up to 104 weeks. Additionally, PRO and patient preference data support the benefit of once weekly dulaglutide for the treatment of T2D. ARTICLE HISTORY

show abstract

Section: Device and Delivery Benefitsmentioning

confidence: 99%

Section: Pros In Dulaglutide Clinical Trialsmentioning

confidence: 99%